Health Care-Aging Solutions

Anti-ageing drug rapamycin may extend life almost as effectively as restricting calories – our new research

by Zahida Sultanova 19/6/25 The Conversation

Eating less, or dietary restriction, has been the gold standard for achieving a longer life ever since a study nearly a century ago in which laboratory rats that ate less surprised scientists by outliving their well-fed lab mates.

‘

‘Initially I thought it was a scam’: can collagen really turn back the clock?

by David Cox 6/11/22 The Guardian

Most collagen proteins consist of long, spindly, flimsy-looking structures called fibrils, which provide it with the strength needed to anchor cells to one another and glue our bones, cartilage and tendons together and yet the flexibility to still allow for movement and agility.

How Deep Sleep May Help The Brain Clear Alzheimer's Toxins

by Jon Hamilton 31/10/2019 NPR

The finding also suggests that people might be able to reduce their risk of Alzheimer's by ensuring that they get high-quality sleep, says William Jagust, a professor of public health and neuroscience at the University of California, Berkeley, who was not involved in the study.

Scientists are already testing other lifestyle changes, like diet and exercise changes, to protect brain health. And sleep should be "high on the list" of measures worth trying, he says.

Alzheimer’s experts greet China’s surprise approval of a drug for brain disease with hope and caution

by ByKelly Servick, Dennis Normile 05/11/2019 Science

A Chinese biotech startup has startled neuroscientists and drug developers with a new plant-based compound it claims improves cognitive function in Alzheimer's patients by altering their gut microbiomes. In mouse studies published earlier this year, this approach reduced inflammation in the brains of rodents engineered to develop Alzheimer's-like pathology. The drug's backers also claim a phase III clinical trial of about 800 people "demonstrated solid and consistent cognition improvement" among those treated versus a control group. Though not yet published, the results convinced China's drug regulator last week to approve the marketing of the drug, known as GV-971, with the condition that additional data be gathered to demonstrate safety and efficacy.